Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood, then genetically modifying them in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
